{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016626","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.371214+00:00","generated_at":"2026-06-02T00:37:06.484774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised","bullets":["Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.","Cash and investments $18.6M as of March 31, 2024.","NEPHRO CRRT study enrollment delayed; top-line data guidance (by Sept 30) to be revised.","Dr. Shakil Aslam appointed Chief Development Officer effective May 20, 2024.","Combined R&D and SG&A expenses decreased to $4.2M from $5.3M year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016626","json":"https://secwatch.observer/filing/0001437749-24-016626.json","markdown":"https://secwatch.observer/filing/0001437749-24-016626.md","text":"https://secwatch.observer/filing/0001437749-24-016626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924016626/0001437749-24-016626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924016626/acrx20240513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:37:06.484774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"425dbbb79d1fe7380bc6464c7c2d364e6d8e6a4a","claim":"TALPHERA, INC. reported the three months ended March 31, 2024 results: net income $4.0 million, EPS $0.16 per basic and diluted share.","evidence_excerpt":"Talphera, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924016626/0001437749-24-016626-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"$4.0 million"},{"label":"EPS","value":"$0.16 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}